Pulmonx Corporation
LUNG
Rank in Stocks
#18871
Pulmonx Corporation is a biomedical technology firm dedicated to developing and... Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
Share Price
$2.80
Last synced: 2026-11-09
Market Cap
$120.26M
Change (1 day)
9.38%
Change (1 year)
33.97%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pulmonx Corporation (LUNG)
Category
Healthcare
EPS for Pulmonx Corporation (LUNG)
EPS as of September 2026 TTM: $-1.00
According to Pulmonx Corporation's latest financial reports, its current EPS (TTM) is $-1.00. At the end of 2025 the company had an EPS of $-1.33, an increase over its 2024 EPS of $-1.44.
EPS history for Pulmonx Corporation from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.00 | -24.81% |
| 2025 | $-1.33 | -7.64% |
| 2024 | $-1.44 | -10.00% |
| 2023 | $-1.60 | 0.63% |
| 2022 | $-1.59 | 17.78% |
| 2021 | $-1.35 | 50.00% |
| 2020 | $-0.90 | 55.17% |
| 2019 | $-0.58 | -34.83% |
| 2018 | $-0.89 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $2.70 | -370.00% |
US
|
|
| $4.09 | -509.00% |
IE
|
|
| $9.45 | -1,045.00% |
US
|
|
| $2.37 | -337.00% |
US
|
|
| $1.77 | -277.00% |
US
|
Questions about Pulmonx Corporation's earnings per share (EPS)
What is Pulmonx Corporation's earnings per share (EPS)?
Pulmonx Corporation's earnings per share (EPS) over the last twelve months is $-1.00, as of Sep 2026.
What was Pulmonx Corporation's earnings per share (EPS) in 2025?
In 2025, Pulmonx Corporation's earnings per share (EPS) was $-1.33, compared with $-1.44 in 2024.
How has Pulmonx Corporation's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Pulmonx Corporation's earnings per share (EPS) was highest in 2020 ($-0.90) and lowest in 2023 ($-1.60).
How does Pulmonx Corporation's earnings per share (EPS) compare with similar companies?
Pulmonx Corporation's earnings per share (EPS) ($-1.00) is lower than that of all 5 similar companies listed above. The highest among them is Stryker Corporation, with $9.45.